Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
HFA 24: The TELESAT Study
Author(s): Nicolas Girerd Added: 1 year ago
HFA 2024 — Investigator, Prof Nicolas Girerd (University Hospital of Nancy, FR) joins us to discuss the findings from the TELESAT study (NCT06312501).This multicenter observational longitudinal cohort study investigated whether a Remote Patient Monitoring (RPM) program (Satelia®Cardio, Satelia) is able to prevent cardiac decompensation by detecting weak signals of decompensation early in patients… View more

Heart Failure

Digital Health
Device-Based Strategies for Guideline-Directed Therapy in Heart Failure
Author(s): Renzo Laborante , Attilio Restivo , Daniela Mele , et al Added: 1 week ago

Heart Failure

Prevention & Chronic Conditions
HFA 24: MONITOR-HF Subgroup Analysis
Author(s): Jasper J Brugts Added: 1 year ago
HFA 24 - We are joined by Dr Jasper J Brugts (Erasmus University Medical Centre, NL) to discuss the findings of a predefined subgroup analysis of the MONITOR-HF study (NTR7672).MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation,… View more

Heart Failure
ESC HF 25: TIM-HF2 Pre-specified Analysis
Author(s): Stefan Stork Added: 2 days ago
ESC HF 25 - A secondary analysis of TIM-HF2 showed that patients residing farther from their cardiologist benefited further from remote patient management (RPM).Prof Stefan Störk (University Hospital Wuerzburg, DE) discusses the findings from a pre-specified, secondary analysis of TIM-HF2, investigating the impact of rurality and travel distance on the effectiveness of RPM in patients… View more

Digital Health

Heart Failure
HFA 23: MONITOR-HF: Improving QoL& Reducing HF Hospitalisations with PAP Monitoring
Author(s): Jasper J Brugts Added: 2 years ago
ESC-HFA 2023 — Dr Jasper Brugts (Thoraxcenter, NL) joins us to outline the findings and summarise the take-home messages from the MONITOR-HF trial (NTR7672). MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation, irrespective of… View more

Heart Failure
Cardiovascular Manifestations in Post-COVID-19 Patients
Author(s): Angela Cozma , Violeta Briciu , Adela Viviana Sitar-Tăut , et al Added: 1 month ago

Heart Failure

Prevention & Chronic Conditions
Comparison of Haemodynamic Responses to Landiolol Versus Esmolol
Author(s): Georgios Koukoulitsios , Kyriaki Tsikritsaki , Georgios Magklaras , et al Added: 1 day ago

Heart Failure

Vascular Disease and Surgery
Frailty in Heart Failure: Insights, Patient Outcomes & Future Directions
Author(s): Karol Mirkowski , Ercole Vellone , Bernadetta Żółkowska , et al Added: 2 months ago

Heart Failure
Quality of Life After AVR
Author(s): Meng He , Jinwei Zhang , Jianbo Yu , et al Added: 4 days ago

Heart Failure
EMPA-KIDNEY: Empagliflozin in Patients with Chronic Kidney Disease
Author(s): William Herrington Added: 6 months ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic